Published in Cancer Weekly, November 13th, 1995
NMP22 is the first nuclear matrix protein-based immunodiagnostic product to be reviewed by the FDA for sale in the United States. Matritech will present its clinical trial data, which the panel will consider. The panel typically makes a non-binding recommendation to the FDA concerning any issues or questions presented to the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.